<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460002</url>
  </required_header>
  <id_info>
    <org_study_id>RE-CAMP</org_study_id>
    <nct_id>NCT03460002</nct_id>
  </id_info>
  <brief_title>Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children</brief_title>
  <acronym>RE-CAMP</acronym>
  <official_title>A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bandim Health Project</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Center for Vitamins and Vaccines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bandim Health Project</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The world is set on eradicating measles and polio infections in the coming decade. Once both
      infections are under control, campaigns with measles and oral polio vaccines will be phased
      out. This might do more harm than good for child survival in low-income countries. Studies
      from the Bandim Health Project in Guinea-Bissau, and elsewhere, have revealed, that the live
      measles and oral polio vaccines have beneficial non-specific effects, i.e. effects on child
      morbidity and mortality unrelated to prevention of the targeted diseases.

      The campaigns are presumed to be most beneficial for children not reached by routine
      vaccination programs, as they are not already protected. However, studies show that prior
      routine or campaign vaccination may boost resistance against unrelated infections. If we
      phase out measles and oral polio campaigns after eradicating their target infections without
      considering the impact on child survival, the drastic decline in child mortality since 1990
      could change direction. We will conduct the first cluster randomized controlled trial to
      evaluate the effect of measles and oral polio campaigns on general child morbidity and
      mortality via the Bandim Health Project. Bandim Health Project runs a Health and Demographic
      Surveillance System in Guinea-Bissau since 1978 and assesses child health interventions'
      real-life effects, via continuous registration of all interventions given to all children,
      and follow-up of individuals. We will conduct the trial in rural Guinea-Bissau monitoring all
      nine health regions, covering 182 clusters, with 18,000 children &lt;5 years. The hypothesis is:
      &quot;measles vaccine and oral polio vaccine campaigns in Guinea-Bissau reduce morbidity and
      mortality among children between 0 and 59 months of age by 20% during the subsequent 18
      months in a context of limited measles and no polio infections.&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome: mortality and hospital admission (measured as a rate)</measure>
    <time_frame>Enrolment to end of study (longest follow-up 2 years)</time_frame>
    <description>Death (registered through follow-up visits, verified by verbal autopsies) or first admission (overnight stay at hospital registered by interview at follow up visits)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Enrolment to end of study (longest follow-up 2 years)</time_frame>
    <description>Death (registered through follow-up visits, verified by verbal autopsies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission</measure>
    <time_frame>Enrolment to end of study (longest follow-up 2 years)</time_frame>
    <description>admission (overnight stay at hospital registered by interview at follow up visits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Enrolment to end of study (longest follow-up 2 years)</time_frame>
    <description>Mid-upper-arm-circumference registered with measurement tape as per UNICEF recommendations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute adverse reactions</measure>
    <time_frame>One month after a child is included in the study</time_frame>
    <description>Health center consultations registered through follow-up visits</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21000</enrollment>
  <condition>Measles Vaccination</condition>
  <condition>Oral Polio Vaccine</condition>
  <condition>Non-specific/Heterologous Effects of Vaccines</condition>
  <condition>Mortality</condition>
  <condition>Morbidity</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>Measles vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral polio vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weighing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In control villages children will be weighed only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles vaccine</intervention_name>
    <description>A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.</description>
    <arm_group_label>Measles vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral polio vaccine</intervention_name>
    <description>A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.</description>
    <arm_group_label>Oral polio vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Children aged 0-59 months living with families registered in the rural
        Bandim Health Project Health and Demographic Surveillance Site are included, provided a
        parent/guardian consent.

        Exclusion Criteria:

          -  the child has temperature &gt; 39.0â—¦C or a severe acute illness as defined by the
             examining nurse

        OR

          -  the child has as a mid upper arm circumference &lt; 110 mm and is older than 6 months
             (most feasible local indicator of AIDS and chronic immunosuppressive disease)

        OR

          -  the child has experienced a severe allergic reaction after previous vaccination, drug
             or food.

        OR

          -  the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is &lt;
             2 months old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ane Fisker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bandim Health Project, Guinea-Bissau and Statens Serum Institute, Research Center for Vitamins and Vaccines, Bandim Health Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Aaby, DMSc,Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bandim Health Project, Guinea-Bissau and Statens Serum Institute, Research Center for Vitamins and Vaccines, Bandim Health Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aksel Jensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Statens Serum Institute, Research Center for Vitamins and Vaccines, Bandim Health Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anshu Varma, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Statens Serum Institute, Research Center for Vitamins and Vaccines, Bandim Health Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amabelia Rodrigues, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bandim Health Project, Guinea-Bissau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amabelia Rodrigues, PhD</last_name>
    <email>a.rodrigues@bandim.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ane Fisker, MD, PhD</last_name>
    <email>abf@ssi.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bandim Health Project</name>
      <address>
        <city>Bissau</city>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ane Fisker, MD</last_name>
      <email>a.fisker@bandim.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <reference>
    <citation>World Health Organization. Global measles and rubella strategic plan: 2012-2020. 2012.</citation>
  </reference>
  <reference>
    <citation>World Health Organization. Polio eradication and endgame strategic plan: 2013-2018. 2013.</citation>
  </reference>
  <reference>
    <citation>Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 â€“ conclusions and recommendations. Wkly Epidemiol Rec. 2015 Dec 11;90(50):681-99. English, French.</citation>
    <PMID>26685390</PMID>
  </reference>
  <reference>
    <citation>Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ. 2000 Dec 9;321(7274):1435-8.</citation>
    <PMID>11110734</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 1995 Aug 19;311(7003):481-5.</citation>
    <PMID>7647643</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Garly ML, BalÃ© C, Martins C, Jensen H, Lisse I, Whittle H. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. Pediatr Infect Dis J. 2003 Sep;22(9):798-805.</citation>
    <PMID>14506371</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Martins CL, Garly ML, BalÃ© C, Andersen A, Rodrigues A, Ravn H, Lisse IM, Benn CS, Whittle HC. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ. 2010 Nov 30;341:c6495. doi: 10.1136/bmj.c6495.</citation>
    <PMID>21118875</PMID>
  </reference>
  <reference>
    <citation>Lund N, Andersen A, Hansen AS, Jepsen FS, Barbosa A, Biering-SÃ¸rensen S, Rodrigues A, Ravn H, Aaby P, Benn CS. The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial. Clin Infect Dis. 2015 Nov 15;61(10):1504-11. doi: 10.1093/cid/civ617. Epub 2015 Jul 28.</citation>
    <PMID>26219694</PMID>
  </reference>
  <reference>
    <citation>Lund N, Biering-SÃ¸rensen S, Andersen A, Monteiro I, Camala L, JÃ¸rgensen MJ, Aaby P, Benn CS. Neonatal vitamin A supplementation associated with a cluster of deaths and poor early growth in a randomised trial among low-birth-weight boys of vitamin A versus oral polio vaccine at birth. BMC Pediatr. 2014 Aug 28;14:214. doi: 10.1186/1471-2431-14-214.</citation>
    <PMID>25163399</PMID>
  </reference>
  <reference>
    <citation>Martins CL, Benn CS, Andersen A, BalÃ© C, Schaltz-Buchholzer F, Do VA, Rodrigues A, Aaby P, Ravn H, Whittle H, Garly ML. A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis. 2014 Jun 1;209(11):1731-8. doi: 10.1093/infdis/jit804. Epub 2014 Jan 16.</citation>
    <PMID>24436454</PMID>
  </reference>
  <reference>
    <citation>SÃ¸rup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014 Feb 26;311(8):826-35. doi: 10.1001/jama.2014.470.</citation>
    <PMID>24570246</PMID>
  </reference>
  <reference>
    <citation>SÃ¸rup S, Stensballe LG, Krause TG, Aaby P, Benn CS, Ravn H. Oral Polio Vaccination and Hospital Admissions With Non-Polio Infections in Denmark: Nationwide Retrospective Cohort Study. Open Forum Infect Dis. 2015 Dec 17;3(1):ofv204. doi: 10.1093/ofid/ofv204. eCollection 2016 Jan.</citation>
    <PMID>26885538</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Hedegaard K, Sodemann M, Nhante E, Veirum JE, Jakobsen M, Lisse I, Jensen H, SandstrÃ¶m A. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau. Vaccine. 2005 Feb 25;23(14):1746-51.</citation>
    <PMID>15705481</PMID>
  </reference>
  <reference>
    <citation>Andersen A, Fisker AB, Rodrigues A, et al. National immunization campaigns with oral polio vaccine (OPV) reduce the general all-cause mortality rate: An analysis of the effect of campaign-OPV on child mortality within seven randomised trials (submitted). 2016.</citation>
  </reference>
  <reference>
    <citation>Fisker AB, Rodrigues A, Martins C, Ravn H, Byberg S, Thysen S, Storgaard L, Pedersen M, Fernandes M, Benn CS, Aaby P. Reduced All-cause Child Mortality After General Measles Vaccination Campaign in Rural Guinea-Bissau. Pediatr Infect Dis J. 2015 Dec;34(12):1369-76. doi: 10.1097/INF.0000000000000896.</citation>
    <PMID>26379164</PMID>
  </reference>
  <reference>
    <citation>Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013 Sep;34(9):431-9. doi: 10.1016/j.it.2013.04.004. Epub 2013 May 14. Review.</citation>
    <PMID>23680130</PMID>
  </reference>
  <reference>
    <citation>Byberg S., Thysen SM, Rodrigues A et al. A general measles vaccination campaign and subsequent child mortality in urban Guinea-Bissau (manuscript).</citation>
  </reference>
  <reference>
    <citation>Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J, Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ. 1993 Nov 20;307(6915):1308-11.</citation>
    <PMID>8257884</PMID>
  </reference>
  <reference>
    <citation>World Bank. World Bank Countries and Lending Groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed 01-07-2016).</citation>
  </reference>
  <reference>
    <citation>United Nations Inter-agency Group for Child Mortality Estimation. http://www.childmortality.org/index.php?r=site/graph#ID=GNB_Guinea-Bissau (accessed 01-07-2016)</citation>
  </reference>
  <reference>
    <citation>INDEPTH network. Indepth Verbal Autopsy. http://www.indepth-network.org/resources/tools (accessed 25-07-2016).</citation>
  </reference>
  <reference>
    <citation>DesgrÃ©es du LoÃ» A, Pison G, Aaby P. Role of immunizations in the recent decline in childhood mortality and the changes in the female/male mortality ratio in rural Senegal. Am J Epidemiol. 1995 Sep 15;142(6):643-52.</citation>
    <PMID>7653475</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Jensen H, Samb B, Cisse B, Sodemann M, Jakobsen M, Poulsen A, Rodrigues A, Lisse IM, Simondon F, Whittle H. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet. 2003 Jun 28;361(9376):2183-8.</citation>
    <PMID>12842371</PMID>
  </reference>
  <reference>
    <citation>Benn CS, Rodrigues A, Yazdanbakhsh M, Fisker AB, Ravn H, Whittle H, Aaby P. The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. Vaccine. 2009 May 11;27(21):2891-8. doi: 10.1016/j.vaccine.2009.02.080. Epub 2009 Mar 9.</citation>
    <PMID>19428899</PMID>
  </reference>
  <reference>
    <citation>Benn CS, Fisker AB, Whittle HC, Aaby P. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. EBioMedicine. 2016 Aug;10:312-7. doi: 10.1016/j.ebiom.2016.07.016. Epub 2016 Jul 15. Review.</citation>
    <PMID>27498365</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. Information Sheet Observed Rate of Vaccine Reactions Measles, Mumps and Rubella Vaccines. 2014. http://www.who.int/vaccine_safety/initiative/tools/MMR_vaccine_rates_ information_sheet.pdf (accessed 01-07-2016).</citation>
  </reference>
  <reference>
    <citation>World Health Organization. Information Sheet Observed Rate of Vaccine Reactions Polio Vaccines. 2014. http://www.who.int/vaccine_safety/initiative/tools/Polio_vaccine_rates_information_sheet.pdf (accessed 01-07-2016).</citation>
  </reference>
  <reference>
    <citation>Chuang SK, Lau YL, Lim WL, Chow CB, Tsang T, Tse LY. Mass measles immunization campaign: experience in the Hong Kong Special Administrative Region of China. Bull World Health Organ. 2002;80(7):585-91. Epub 2002 Jul 30.</citation>
    <PMID>12163924</PMID>
  </reference>
  <reference>
    <citation>Abedi GR, Mutuc JD, Lawler J, Leroy ZC, Hudson JM, Blog DS, Schulte CR, Rausch-Phung E, Ogbuanu IU, Gallagher K, Kutty PK. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine. 2012 Nov 19;30(49):7052-8. doi: 10.1016/j.vaccine.2012.09.053. Epub 2012 Oct 3.</citation>
    <PMID>23041123</PMID>
  </reference>
  <reference>
    <citation>Arruda WO, Kondageski C. Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, ParanÃ¡, Brazil, 1998. Rev Inst Med Trop Sao Paulo. 2001 Sep-Oct;43(5):301-2.</citation>
    <PMID>11696855</PMID>
  </reference>
  <reference>
    <citation>Roberts RJ, Sandifer QD, Evans MR, Nolan-Farrell MZ, Davis PM. Reasons for non-uptake of measles, mumps, and rubella catch up immunisation in a measles epidemic and side effects of the vaccine. BMJ. 1995 Jun 24;310(6995):1629-32.</citation>
    <PMID>7795447</PMID>
  </reference>
  <reference>
    <citation>Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles Vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines: Saunders; 2008: 353-98.</citation>
  </reference>
  <reference>
    <citation>Fisker AB, Bale C, JÃ¸rgensen MJ, Balde I, HornshÃ¸j L, Bibby BM, Aaby P, Benn CS. High-dose vitamin A supplementation administered with vaccinations after 6 months of age: sex-differential adverse reactions and morbidity. Vaccine. 2013 Jun 28;31(31):3191-8. doi: 10.1016/j.vaccine.2013.04.072. Epub 2013 May 14.</citation>
    <PMID>23680441</PMID>
  </reference>
  <reference>
    <citation>Sugawara T, Ohsuka Y, Taya K, Yasui Y, Wada N, Sakano M, Koshida R, Fujii F, Shibata S, Hashimoto G, Utsumi H, Sumitomo M, Ishihara M, Kondo H, Sato H, Ueno K, Araki K, Okabe N. Diarrhea as a minor adverse effect due to oral polio vaccine. Jpn J Infect Dis. 2009 Jan;62(1):51-3.</citation>
    <PMID>19168959</PMID>
  </reference>
  <reference>
    <citation>Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 â€“ conclusions and recommendations. Wkly Epidemiol Rec. 2013 May 17;88(20):201-6. English, French.</citation>
    <PMID>23696983</PMID>
  </reference>
  <reference>
    <citation>Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines . Available at: http://www.who.int/immunization/sage/meetings /2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf?ua=1, 2014.</citation>
  </reference>
  <reference>
    <citation>Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 â€“- conclusions and recommendations. Wkly Epidemiol Rec. 2014 May 23;89(21):221-36. English, French.</citation>
    <PMID>24864348</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Gustafson P, Roth A, Rodrigues A, Fernandes M, Sodemann M, Holmgren B, Benn CS, Garly ML, Lisse IM, Jensen H. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine. 2006 Jul 17;24(29-30):5718-25. Epub 2006 May 6.</citation>
    <PMID>16720061</PMID>
  </reference>
  <reference>
    <citation>Jensen ML, Dave S, Schim van der Loeff M, da Costa C, Vincent T, Leligdowicz A, Benn CS, Roth A, Ravn H, Lisse IM, Whittle H, Aaby P. Vaccinia scars associated with improved survival among adults in rural Guinea-Bissau. PLoS One. 2006 Dec 20;1:e101.</citation>
    <PMID>17183634</PMID>
  </reference>
  <reference>
    <citation>Rieckmann A, Villumsen M, SÃ¸rup S, Haugaard LK, Ravn H, Roth A, Baker JL, Benn CS, Aaby P. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. Int J Epidemiol. 2017 Apr 1;46(2):695-705. doi: 10.1093/ije/dyw120.</citation>
    <PMID>27380797</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Measles vaccine</keyword>
  <keyword>Oral polio vaccine</keyword>
  <keyword>Campaign</keyword>
  <keyword>Child mortality</keyword>
  <keyword>Child morbidity</keyword>
  <keyword>Non-specific effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

